Clinical trials: HER2-positive Breast Cancer
Breast Cancer
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
This multicenter study in participants with HER2-positive eBC will investigate participants' pain and discomfort of SC trastuzumab (Herceptin) administered either via a single-use injection device (SID) or via vial for manual…
- Trial name
- ESCAPE (NCT02194166)
- Testing
- Trastuzumab, Paclitaxel, Docetaxel
- Where
- 7 sites in Belarus, Kazakhstan
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms, Secondary
Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.
- Conditions
- Breast Neoplasms, Secondary, HER2 Positive Carcinoma of Breast
- Trial name
- IJBMNZrT003 (NCT01420146)
- Testing
- Zr89-trastuzumab
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Breast Cancer
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
In this phase II trial the investigators propose to evaluate ixabepilone in combination with carboplatin and trastuzumab as neoadjuvant therapy in locally advanced breast cancer patients.
- Trial name
- NCT00821886
- Testing
- Ixabepilone, Trastuzumab, Carboplatin
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT07318805
- Testing
- PF-08032562, Fulvestrant, Cetuximab
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- Pfizer
Metastatic Breast Cancer
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression
This is an open-label, single arm, multicenter phase II study evaluating treatment with pembrolizumab in combination with paclitaxel in patients with locally advanced or metastatic non-luminal hormone receptor-positive (HR+)…
- Trial name
- TATEN (NCT04251169)
- Testing
- Pembrolizumab, Paclitaxel
- Where
- 7 sites in Spain
- Volunteers
- 20 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer, Her 2 Positive Breast Cancer
Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease
The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings.
- Trial name
- PERTUREAL (NCT07542496)
- Where
- 2 sites in Algeria
- Volunteers
- 1,000 people
- Sponsor
- Société Algérienne de Formation et Recherche en Oncologie
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
This phase Ib/II trial studies the side effects and best dose of ribociclib, tucatinib, and trastuzumab for the treatment of HER2 positive breast cancer that has spread to other parts of the body (metastatic), and then compares…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT05319873
- Testing
- Carboplatin, Docetaxel, Fulvestrant
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Breast Cancer
Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer
This is a multicenter, open-label, single-arm, phase II clinical trial, phase II trial will evaluate the efficacy and safety of olaparib plus trastuzumab in patients with HER2[+], BRCA-mutated advanced breast cancer
- Trial name
- OPHELIA (NCT03931551)
- Testing
- Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]
- Where
- 4 sites in Spain
- Volunteers
- 5 people
- Sponsor
- MedSIR
HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression
Testing a New Imaging Agent to Identify Cancer
The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.
- Conditions
- HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression, HER2-positive Metastatic Breast Cancer
- Trial name
- NCT04692831
- Testing
- 89Zr-ss-pertuzumab PET/CT
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
This study will compare the anti-tumor efficacy of apricoxib and lapatinib/capecitabine with placebo and lapatinib/capecitabine as measured by time to disease progression and evaluate urinary PGE-M measurements or baseline COX-2…
- Trial name
- APRiCOT-B (NCT00657137)
- Testing
- apricoxib + lapatinib + capecitabine
- Where
- 44 sites in United States
- Volunteers
- 12 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Breast Cancer
A Study of ZN-c5 in Participants With Breast Cancer
This is a Phase 1 open-label, multicenter study to evaluate biomarkers for ZN-c5 in subjects with breast cancer
- Trial name
- NCT04176757
- Testing
- ZN-c5
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Zeno Alpha Inc.
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
This phase II trial studies the side effects and how well giving paclitaxel and cyclophosphamide with or without trastuzumab before surgery works in treating patients with previously untreated breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01750073
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- University of Nebraska
Metastatic Breast Cancer
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+…
- Trial name
- NCT06018337
- Testing
- DB-1303/BNT323, Capecitabine, Paclitaxel
- Where
- 258 sites in United States, Argentina and 15 more
- Volunteers
- 541 people
- Sponsor
- DualityBio Inc.
Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS.
- Conditions
- Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT02774681
- Testing
- Cognitive Assessment, Palbociclib, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Breast Cancer
Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer
- Trial name
- Opti-HER (NCT01669239)
- Testing
- Liposomal Doxorubicin
- Where
- 19 sites in Spain
- Volunteers
- 83 people
- Sponsor
- SOLTI Breast Cancer Research Group
ER-positive Her2-negative Early Breast Cancer
Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer
The need/benefit of adjuvant chemotherapy could be negligible for a certain category of patient with newly diagnosed unilateral non metastatic breast cancer.
- Trial name
- OPTIGEN (NCT03080428)
- Testing
- Genomic test
- Sponsor
- UNICANCER
Breast Cancer
Treatment Patterns of Neratinib in HER2+ EBC in China
This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China
- Trial name
- NCT05491057
- Testing
- Neratinib
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Pierre Fabre Medicament
Neoplasms, Breast
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
This study will characterize the effect of elevated gastric pH mediated by the proton-pump inhibitor, esomeprazole, on the relative bioavailability of lapatinib in subjects with metastatic ErbB2 positive breast cancer.
- Trial name
- NCT00849329
- Testing
- lapatinib, lapatinib plus esomeprazole
- Where
- 4 sites in United States, South Korea and 1 more
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Breast Neoplasm Female
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
The management of HR-positive, HER2-negative metastatic breast cancer includes endocrine monotherapy or combination regimens, both with benefit diminishing as resistance develops.
- Trial name
- NCT05075512
- Testing
- anlotinib, fulvestrant
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Breast Cancer Female
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
The purpose of this study is to learn more about how to treat patients with HER-2/neu positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be over-expressed in aggressive breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer
- Trial name
- NCT03387553
- Testing
- Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.